Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Net Margin (2016 - 2025)

Cytosorbents (CTSO) has disclosed Net Margin for 14 consecutive years, with 33.42% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Margin fell 632.0% year-over-year to 33.42%, compared with a TTM value of 45.33% through Sep 2025, up 834.0%, and an annual FY2024 reading of 58.21%, up 3588.0% over the prior year.
  • Net Margin was 33.42% for Q3 2025 at Cytosorbents, up from 44.0% in the prior quarter.
  • Across five years, Net Margin topped out at 8.16% in Q4 2022 and bottomed at 150.42% in Q3 2022.
  • Average Net Margin over 5 years is 66.48%, with a median of 65.64% recorded in 2021.
  • Peak annual rise in Net Margin hit 7816bps in 2022, while the deepest fall reached -8916bps in 2022.
  • Year by year, Net Margin stood at 86.32% in 2021, then soared by 91bps to 8.16% in 2022, then tumbled by -830bps to 75.84% in 2023, then dropped by -14bps to 86.16% in 2024, then skyrocketed by 61bps to 33.42% in 2025.
  • Business Quant data shows Net Margin for CTSO at 33.42% in Q3 2025, 44.0% in Q2 2025, and 16.94% in Q1 2025.